Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The overall goals of this study are to compare the safety and efficacy of daptomycin
monotherapy 10 mg/kg/day and vancomycin monotherapy dosed to achieve vancomycin trough levels
of 15 to 20 μg/mL for the treatment of methicillin-resistant S. aureus bacteremia (MRSA),
including right-sided infective endocarditis (RIE).